Condition: Psoriasis · Sponsor: Psoriasis Treatment Center of Central New Jersey
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
This description comes directly from the study's public registry record.
Jerry Bagel, MD · 6094434500 · dreamacres1@aol.com
Elise Nelson · 6094434500 · enelson@windsordermatology.com
Always discuss trial participation with your own doctor first.
| Psoriasis Treatment Center of Central New Jersey | East Windsor, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03827876